SG11201406548WA - Anti-malarial agents - Google Patents
Anti-malarial agentsInfo
- Publication number
- SG11201406548WA SG11201406548WA SG11201406548WA SG11201406548WA SG11201406548WA SG 11201406548W A SG11201406548W A SG 11201406548WA SG 11201406548W A SG11201406548W A SG 11201406548WA SG 11201406548W A SG11201406548W A SG 11201406548WA SG 11201406548W A SG11201406548W A SG 11201406548WA
- Authority
- SG
- Singapore
- Prior art keywords
- dundee
- international
- ddi
- nethergate
- university
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 17 October 2013 (17.10.2013) WIPOIPCT (10) International Publication Number WO 2013/153357 A1 (51) International Patent Classification: C07D 215/52 (2006.01) A61P 33/06 (2006.01) A61K31/4725 (2006.01) (21) International Application Number: PCT/GB2013/050633 (22) International Filing Date: 14 March 2013 (14.03.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1206280.8 10 April 2012 (10.04.2012) GB (71) Applicant: UNIVERSITY OF DUNDEE [GB/GB]; Neth- ergate, Dundee, DDI 4HN (GB). (72) Inventors: GILBERT, Ian Hugh; c/o University of Dun dee, Nethergate, Dundee, DDI 4HN (GB). NORCROSS, Neil; c/o University of Dundee, Nethergate, Dundee, DDI 4HN (GB). BARAGANA RUIBAL, Beatriz; c/o Univer sity of Dundee, Nethergate, Dundee, DDI 4HN (GB). PORZELLE, Achim; c/o Peakdale Molecular Ltd, Peak- dale Science Park, Sheffield Road, Chapel-en-le-Frith, High Peak SK23 0PG (GB). (74) Agent: HARRISON GODDARD FOOTE; Delta House, 50 West Nile Street, Glasgow, G1 2NP (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: ANTI-MALARIAL AGENTS l> m m T-H o CJ (57) Abstract: The present invention relates to a novel class of quinolone-4-carboxamide Pf5D7 inhibitors of general formula (I) (Formula (I)) wherein R , R , R , 1 2 3 R , R , 4 5 R , 6 R , 7 R 8 and X are as defined herein, their to use in medicine, and in the treatment of mal aria in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1206280.8A GB201206280D0 (en) | 2012-04-10 | 2012-04-10 | Anti-malarial agents |
| PCT/GB2013/050633 WO2013153357A1 (en) | 2012-04-10 | 2013-03-14 | Anti-malarial agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201406548WA true SG11201406548WA (en) | 2015-01-29 |
Family
ID=46177063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201406548WA SG11201406548WA (en) | 2012-04-10 | 2013-03-14 | Anti-malarial agents |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9115088B2 (en) |
| EP (1) | EP2836483B1 (en) |
| JP (1) | JP6088639B2 (en) |
| CN (1) | CN104302624B (en) |
| BR (1) | BR112014025416B1 (en) |
| CA (1) | CA2870140C (en) |
| ES (1) | ES2587683T3 (en) |
| GB (1) | GB201206280D0 (en) |
| HU (1) | HUE030572T2 (en) |
| IN (1) | IN2014DN09314A (en) |
| MY (1) | MY166153A (en) |
| PH (1) | PH12014502285A1 (en) |
| PT (1) | PT2836483T (en) |
| SG (1) | SG11201406548WA (en) |
| WO (1) | WO2013153357A1 (en) |
| ZA (1) | ZA201408094B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201610724D0 (en) | 2016-06-20 | 2016-08-03 | Univ Dundee | Anti-infective agents |
| CN108101842B (en) * | 2017-12-29 | 2021-04-30 | 山东诚汇双达药业有限公司 | Preparation method of 2-hydroxy-4-carboxyquinoline |
| JP7391036B2 (en) * | 2018-04-11 | 2023-12-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination of quinoline-4-carboxamide and benzonaphthyridine derivatives as an antimalarial combination drug. |
| CN111084774B (en) * | 2019-11-29 | 2021-06-15 | 中国科学院广州生物医药与健康研究院 | Application of pyrrolidine compound composition in preparation of antimalarial drugs |
| CN114829351A (en) * | 2020-01-21 | 2022-07-29 | 卫材R&D管理有限公司 | Novel antimalarial agents containing heterocyclic compounds |
| EP3892332A1 (en) * | 2020-04-09 | 2021-10-13 | University Of Kentucky Research Foundation | New anti-malarial agents |
| WO2024089045A1 (en) * | 2022-10-24 | 2024-05-02 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Tasl mimicking molecules and applications thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2502264A (en) * | 1946-06-25 | 1950-03-28 | Us Sec War | Quinoline derivatives having antimalarial properties |
| JPH0873355A (en) * | 1994-09-02 | 1996-03-19 | Mitsui Toatsu Chem Inc | Agent overcoming tolerance to antimalarial drugs |
| TR199800854T2 (en) * | 1995-11-16 | 1998-08-21 | F.Hoffmann-La Roche Ag | Antis�tma quinoline turret. |
| AU757059B2 (en) * | 1997-06-19 | 2003-01-30 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| AU2006305538B2 (en) * | 2005-10-21 | 2012-06-28 | Idorsia Pharmaceuticals Ltd | Piperazine derivatives as antimalarial agents |
-
2012
- 2012-04-10 GB GBGB1206280.8A patent/GB201206280D0/en not_active Ceased
-
2013
- 2013-03-14 SG SG11201406548WA patent/SG11201406548WA/en unknown
- 2013-03-14 CA CA2870140A patent/CA2870140C/en active Active
- 2013-03-14 BR BR112014025416A patent/BR112014025416B1/en active IP Right Grant
- 2013-03-14 JP JP2015505014A patent/JP6088639B2/en active Active
- 2013-03-14 MY MYPI2014002888A patent/MY166153A/en unknown
- 2013-03-14 IN IN9314DEN2014 patent/IN2014DN09314A/en unknown
- 2013-03-14 CN CN201380025617.2A patent/CN104302624B/en active Active
- 2013-03-14 PT PT137111100T patent/PT2836483T/en unknown
- 2013-03-14 EP EP13711110.0A patent/EP2836483B1/en active Active
- 2013-03-14 HU HUE13711110A patent/HUE030572T2/en unknown
- 2013-03-14 WO PCT/GB2013/050633 patent/WO2013153357A1/en active Application Filing
- 2013-03-14 ES ES13711110.0T patent/ES2587683T3/en active Active
- 2013-03-14 US US14/391,394 patent/US9115088B2/en active Active
-
2014
- 2014-10-10 PH PH12014502285A patent/PH12014502285A1/en unknown
- 2014-11-05 ZA ZA2014/08094A patent/ZA201408094B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201206280D0 (en) | 2012-05-23 |
| PH12014502285B1 (en) | 2014-12-15 |
| EP2836483B1 (en) | 2016-07-27 |
| EP2836483A1 (en) | 2015-02-18 |
| HUE030572T2 (en) | 2017-05-29 |
| CN104302624A (en) | 2015-01-21 |
| CA2870140C (en) | 2018-06-26 |
| MY166153A (en) | 2018-06-06 |
| PT2836483T (en) | 2016-08-26 |
| JP2015512930A (en) | 2015-04-30 |
| CN104302624B (en) | 2016-01-13 |
| CA2870140A1 (en) | 2013-10-17 |
| IN2014DN09314A (en) | 2015-07-10 |
| ZA201408094B (en) | 2017-08-30 |
| US20150045354A1 (en) | 2015-02-12 |
| PH12014502285A1 (en) | 2014-12-15 |
| WO2013153357A1 (en) | 2013-10-17 |
| US9115088B2 (en) | 2015-08-25 |
| ES2587683T3 (en) | 2016-10-26 |
| BR112014025416A2 (en) | 2013-10-17 |
| JP6088639B2 (en) | 2017-03-01 |
| BR112014025416A8 (en) | 2018-06-12 |
| BR112014025416B1 (en) | 2020-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201406548WA (en) | Anti-malarial agents | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201900947RA (en) | Tlr7/8 antagonists and uses thereof | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201810171SA (en) | Kras g12c inhibitors | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201408238WA (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201408791TA (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201909083UA (en) | Piperidines as covalent menin inhibitors | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201407326XA (en) | Compositions and methods for treatment of mucositis |